AR046222A1 - Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivados - Google Patents
Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivadosInfo
- Publication number
- AR046222A1 AR046222A1 ARP040103986A ARP040103986A AR046222A1 AR 046222 A1 AR046222 A1 AR 046222A1 AR P040103986 A ARP040103986 A AR P040103986A AR P040103986 A ARP040103986 A AR P040103986A AR 046222 A1 AR046222 A1 AR 046222A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- defined above
- hydrogen
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una formulación de dosis de liberación controlada, caracterizada porque comprende un compuesto de la fórmula (1), en la cual: R1y R2 son, independientemente, hidrógeno, alquilo C1-6, fenilo o bencilo; o R1 y R2, tomados en conjunto, son bencilideno opcionalmente sustituido con R3 como se define más adelante o alquilideno de hasta 6 átomos de carbono; o R1 y R2, tomados en conjunto con el átomo de carbono al cual están unidos, forman un residuo carbonilo o un grupo cicloalquilo que tiene hasta 6 átomos de carbono; R3 es hidrógeno, hidroxi, halógeno, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, arilalcoxi C7-12, alcanoiloxi C2-6, amino, mono- o di-alquilamino en el cual cada grupo alquilo C1-6, alcanamido C2-6 o alcanosulfonamido C1-6; R4 es hidrógeno o alquilo C1-6; n es uno de los números enteros 0, 1, 2, 3, 4, 5, ó 6; Z es hidrógeno, hidroxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, cicloalquilo C3-8, alquilo policíclico C7-15, fenilo opcionalmente sustituido con R3 como se ha definido antes, fenoxi, opcionalmente sustituido con R3 como se ha definido antes, naftilo opcionalmente sustituido con R3 como se ha definido antes o naftiloxi opcionalmente sustituido con R3 como se ha definido antes, heteroarilo o heteroariloxi, en donde el anillo heterocíclico del grupo heteroarilo o heteroariloxi es seleccionado de tiofeno, furano, piridina, pirazina, pirimidina, indol, indazol imidazol, cromano, cumarina, carboestirilo, quinolina, bencisoxazol, benzoxazol, pirazol, pirrol, tiazol, oxazol, o isoxazol y el anillo heterocíclico está opcionalmente sustituido por R3 como se ha definido antes; o una sal farmacéuticamente aceptable de lo mismo. Reivindicación 22: Un método de tratamiento para un desorden del sistema dopaminérgico, caracterizado porque comprende administrar a un paciente que necesita de dicho tratamiento una formulación de dosis de liberación controlada de acuerdo a cualquiera de las reivindicaciones 1-21. Reivindicación 53: Un conjunto de formas de dosis de liberación controlada, caracterizado porque comprende una pluralidad de formas de dosis de liberación controlada individuales, en donde cada forma de dosis individual comprende una cantidad diferente de dicho compuesto de acuerdo a las reivindicaciones 1, 7 o 17.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51531503P | 2003-10-29 | 2003-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046222A1 true AR046222A1 (es) | 2005-11-30 |
Family
ID=34572826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103986A AR046222A1 (es) | 2003-10-29 | 2004-10-29 | Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivados |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US20050095292A1 (es) |
| EP (1) | EP1675583B1 (es) |
| JP (1) | JP5547865B2 (es) |
| KR (1) | KR101409724B1 (es) |
| CN (2) | CN1874767A (es) |
| AR (1) | AR046222A1 (es) |
| AU (1) | AU2004286855B2 (es) |
| BR (1) | BRPI0415953B8 (es) |
| CA (1) | CA2543045C (es) |
| ES (1) | ES2405404T3 (es) |
| GT (1) | GT200400218A (es) |
| HK (1) | HK1089394A1 (es) |
| IL (1) | IL174958A (es) |
| MX (1) | MXPA06004752A (es) |
| NO (1) | NO20062004L (es) |
| PA (1) | PA8616201A1 (es) |
| PE (1) | PE20050484A1 (es) |
| RU (1) | RU2376988C2 (es) |
| SG (1) | SG147450A1 (es) |
| TW (1) | TW200517106A (es) |
| WO (1) | WO2005044262A1 (es) |
| ZA (1) | ZA200603409B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200400218A (es) | 2003-10-29 | 2005-06-06 | Formulaciones de liberacion sostenida. | |
| US8858993B2 (en) | 2005-07-25 | 2014-10-14 | Metrics, Inc. | Coated tablet with zero-order or near zero-order release kinetics |
| WO2007025182A2 (en) * | 2005-08-26 | 2007-03-01 | Bpsi Holdings, Inc. | Drug compositions containing controlled release hypromellose matrices |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| HUE026400T2 (en) * | 2008-12-22 | 2016-06-28 | Novartis Ag | Dosage Scheme for S1P Receptor Agonist |
| DK3061821T3 (da) | 2009-07-22 | 2019-08-26 | PureTech Health LLC | Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| EA026144B9 (ru) | 2011-01-07 | 2021-10-26 | Новартис Аг | Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая |
| US10137093B2 (en) * | 2011-08-16 | 2018-11-27 | Cardiora Pty Ltd. | Milrinone controlled-release formulation |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| CA2882713A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016101024A1 (en) | 2014-12-22 | 2016-06-30 | Baker Idi Heart & Diabetes Institute Holdings Limited | Method of treatment |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| PE20200732A1 (es) | 2017-06-21 | 2020-07-23 | Minerva Neurosciences Inc | Formas de dosificacion oral y de liberacion controlada gastrorresistentes |
| US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
| JP6983139B2 (ja) * | 2017-11-27 | 2021-12-17 | 信越化学工業株式会社 | 固形製剤用組成物並びに固形製剤及びその製造方法 |
| CA3087932A1 (en) | 2018-01-09 | 2019-07-18 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
| KR102408292B1 (ko) * | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| CN113559074B (zh) * | 2020-06-28 | 2023-04-21 | 海创药业股份有限公司 | 一种喹啉类化合物缓释片及其制备方法 |
| CN116549406B (zh) * | 2023-05-23 | 2023-12-19 | 北京丰科睿泰医药科技有限公司 | 一种盐酸曲唑酮缓释片剂 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
| JP2687448B2 (ja) * | 1988-06-22 | 1997-12-08 | 大正製薬株式会社 | イブプロフェン徐放性製剤 |
| US5028434A (en) * | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
| US4988679A (en) * | 1989-01-03 | 1991-01-29 | Leonard Chavkin | Liquid sustained release composition |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| WO1991013872A1 (en) | 1990-03-15 | 1991-09-19 | The Upjohn Company | Therapeutically useful heterocyclic indole compounds |
| JP2600978B2 (ja) * | 1990-05-25 | 1997-04-16 | 日産自動車株式会社 | サスペンションのアッパリンク支持部構造 |
| US5128366A (en) * | 1990-07-05 | 1992-07-07 | Shinogi & Co., Ltd. | Pyrrole derivatives |
| US5168387A (en) * | 1990-12-11 | 1992-12-01 | Central Glass Company, Limited | Variable light transmittance device |
| US5633376A (en) * | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
| JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
| US5166367A (en) | 1991-06-21 | 1992-11-24 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5126366A (en) | 1991-06-21 | 1992-06-30 | American Home Products Corporation | Aminophenoxyalkyl derivatives of benzodioxan |
| US5189171A (en) | 1991-06-21 | 1993-02-23 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5235055A (en) * | 1992-09-02 | 1993-08-10 | American Home Products Corporation | Antipsychotic quinoline derivatives of benzodioxanmethylamine |
| US5245051A (en) * | 1992-09-03 | 1993-09-14 | American Home Products Corporation | Antipsychotic chroman derivatives of benzodioxanmethylamine |
| EP0605033B1 (en) | 1992-12-21 | 1999-07-21 | Duphar International Research B.V | Enzymatic process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer |
| GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| US5756532A (en) * | 1995-11-06 | 1998-05-26 | American Home Products Corporation | Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives |
| US6126970A (en) * | 1995-12-01 | 2000-10-03 | Janssen Pharmaceutica N.V. | Cisapride sustained release |
| JPH09315969A (ja) * | 1996-05-24 | 1997-12-09 | Taiyo Yakuhin Kogyo Kk | イブジラスト含有徐放性医薬品組成物及びその製造方法 |
| GB9627005D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
| GB9704948D0 (en) | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
| IL123716A (en) | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| AU779955B2 (en) * | 1999-07-13 | 2005-02-24 | Alpha Research Group, Llc | Compositions and methods for the treatment of Parkinson's disease |
| ATE288269T1 (de) * | 1999-12-03 | 2005-02-15 | Polichem Sa | Arzneizusammensetzungen und herstellungsverfahren von ergotalkaloidhaltigen arzneizusammensetzungen mit verzögerter wirkstoffabgabe und verbesserter bioverfügbarkeit |
| US6350773B1 (en) * | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
| NZ519381A (en) | 1999-12-10 | 2004-04-30 | Wyeth Corp | New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
| US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| RU2351316C2 (ru) * | 2003-09-02 | 2009-04-10 | Пфайзер Продактс Инк. | Лекарственные формы с замедленным высвобождением зипразидона |
| GT200400218A (es) | 2003-10-29 | 2005-06-06 | Formulaciones de liberacion sostenida. | |
| TW200811182A (en) | 2006-05-25 | 2008-03-01 | Wyeth Corp | Oxindoledioxans, synthesis thereof, and intermediates thereto |
-
2004
- 2004-10-28 GT GT200400218A patent/GT200400218A/es unknown
- 2004-10-28 PA PA20048616201A patent/PA8616201A1/es unknown
- 2004-10-28 CN CNA2004800319308A patent/CN1874767A/zh active Pending
- 2004-10-28 TW TW093132737A patent/TW200517106A/zh unknown
- 2004-10-28 US US10/975,254 patent/US20050095292A1/en not_active Abandoned
- 2004-10-28 MX MXPA06004752A patent/MXPA06004752A/es active IP Right Grant
- 2004-10-28 CA CA2543045A patent/CA2543045C/en not_active Expired - Fee Related
- 2004-10-28 EP EP04818331A patent/EP1675583B1/en not_active Expired - Lifetime
- 2004-10-28 WO PCT/US2004/036013 patent/WO2005044262A1/en active Application Filing
- 2004-10-28 CN CN2011102045501A patent/CN102335116A/zh active Pending
- 2004-10-28 KR KR1020067008178A patent/KR101409724B1/ko active IP Right Grant
- 2004-10-28 PE PE2004001037A patent/PE20050484A1/es not_active Application Discontinuation
- 2004-10-28 AU AU2004286855A patent/AU2004286855B2/en not_active Ceased
- 2004-10-28 JP JP2006538307A patent/JP5547865B2/ja not_active Expired - Lifetime
- 2004-10-28 RU RU2006118321/15A patent/RU2376988C2/ru active
- 2004-10-28 BR BRPI0415953A patent/BRPI0415953B8/pt not_active IP Right Cessation
- 2004-10-28 ES ES04818331T patent/ES2405404T3/es not_active Expired - Lifetime
- 2004-10-28 SG SG200807793-5A patent/SG147450A1/en unknown
- 2004-10-29 AR ARP040103986A patent/AR046222A1/es unknown
-
2006
- 2006-04-11 IL IL174958A patent/IL174958A/en active IP Right Grant
- 2006-04-28 ZA ZA200603409A patent/ZA200603409B/xx unknown
- 2006-05-04 NO NO20062004A patent/NO20062004L/no not_active Application Discontinuation
- 2006-10-17 HK HK06111340.8A patent/HK1089394A1/xx not_active IP Right Cessation
-
2018
- 2018-03-05 US US15/912,438 patent/US10292966B2/en not_active Expired - Lifetime
- 2018-08-08 US US16/058,769 patent/US10463648B2/en not_active Expired - Lifetime
-
2019
- 2019-11-01 US US16/672,296 patent/US11179369B2/en not_active Expired - Lifetime
-
2022
- 2022-05-27 US US17/827,560 patent/US20230061743A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046222A1 (es) | Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivados | |
| AU2014221799B2 (en) | Novel pyrazole derivative | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| JP5816630B2 (ja) | ナフチリジン誘導体 | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| EA200800478A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| BRPI0815154B1 (pt) | Compostos de indol, composição, e, método de preparação da mesma | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| PE20080671A1 (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR004284A1 (es) | Derivados de aminometil-2,3,8,9-tetrahidro-7h-1,4-dioxino-2,3-e-indol-8-onas y el uso de los mismos para la manufactura de un medicamento | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| AR067845A1 (es) | Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica | |
| AR045143A1 (es) | Compuestos de indazol 3,5- distribuidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular | |
| BR112017004141B1 (pt) | Agente de imagemamento e seu uso | |
| EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| JPWO2011071109A1 (ja) | アミノ基を有する縮合ヘテロ環化合物 | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| PE20091818A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |